The following is a press release from Caris Life Sciences about a breakthrough presentation of data at the recent American Society for Clinical Oncology (ASCO) meeting. In this study, the median overall survival was eight years longer in ovarian and fallopian tube cancer patients treated using Caris Molecular Intelligence profiling vs. those who did not. In a subset of patients who recurred, using this technology patients lived two and a half years longer. The details are summarized in the release as follows:
IRVING, Texas, June 5, 2014 /PRNewswire/ — Caris Life Sciences® and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend. This data, focusing on patients with ovarian cancer, demonstrated significant improvement in survival in women with ovarian cancer.
“We have long hypothesized that personalizing ovarian cancer therapy selection through tumor profiling would benefit patients, and this study is a promising step forward in validating that premise for these patients,” said William McGuire, M.D., Inova Fairfax Hospital.
Additionally, this data demonstrates the importance of avoiding inappropriate therapy. “We have found that the underlying biology is also a powerful predictor of therapies that should be avoided for ovarian cancer patients. Patients who receive a cytotoxic agent when their tumor is not likely to respond, experience a significant negative impact on survival,” said David Spetzler, Ph.D., Vice President, Research & Development, Caris Life Sciences. “Thus a patient’s outcome is strongly influenced by the ability to select appropriate therapies and avoid inappropriate therapies enhanced with the knowledge of the underlying tumor biology provided by Caris Molecular Intelligence™ service.”
Based on a 450 patient cohort, this data reported that treatments consistent with the predictions of molecular profiling significantly improved overall survival in patients with ovarian, primary peritoneal and fallopian tube carcinomas. Patients were stratified based on the chemotherapeutic agents administered during the course of their disease. Of the 450 patients, there were 278 that could be grouped into two cohorts, those whose treatments were predicted to be of benefit (170) and those who received at least one treatment predicted to be of lack of benefit (178). There were no significant differences in the baseline characteristics of these two cohorts.
Select highlights from this clinical study include:
Patients in the Benefit cohort experienced significantly longer post-profiling survival, as evidenced by a 46 percent reduction in the risk of death, compared to the Lack of Benefit cohort (Hazard Ratio = 0.54, 95 percent CI 0.37-0.80; p=0.0018).
Median overall survival observed for patients included in the Benefit cohort (158.0 months) compared to patients included in the Lack of Benefit cohort (63.4 months).
Patients in the Benefit cohort also trended toward significantly longer overall survival, as evidenced by a 31 percent reduction in the risk of death, compared to the Lack of Benefit cohort (Hazard Ratio = 0.69, 95 percent CI 0.47-1.02; p=0.065).
The bottom line is summarized by this brief video clip about this data set showing efficacy of using this technology in ovarian cancer chemotherapy. This is highly encouraging and the data-set is only growing further which improves the value of using this type of tumor profiling.
Tumor profiling is the mainstream best that today has to offer in crafting personalized integrative oncology care. The science behind this is rapidly evolving and is not quite at a level that it can help all cancer patients by any means, but in my opinion it is well on track for groundbreaking ongoing results.
Take a look and listen to the video in this link and the one below. The concept is the same for all cancers, including gynecologic malignancies. Can Molecular Profiling Lower Cancer Costs Medscape
Can Molecular Profiling Lower Cancer Costs Medscape. Joining me are Dr Mike Pishvaian assistant professor at Georgetown in the Hematology Oncology Department at Lombardi Comprehensive Cancer Center and Dr Kenneth Russell director of clinical affairs international for Caris Life Sciences in Basel and more.…